Stockscreener 앱 받기
6.545
3.56%
0.225
시간 외 거래:
6.52
-0.025
-0.38%
전일 마감가:
$6.32
열려 있는:
$6.42
하루 거래량:
109.54K
Relative Volume:
1.63
시가총액:
$2.26M
수익:
$15.74M
순이익/손실:
$-12.86M
주가수익비율:
-0.0283
EPS:
-231.1302
순현금흐름:
$-8.71M
1주 성능:
-29.26%
1개월 성능:
-43.68%
6개월 성능:
-97.92%
1년 성능:
-96.69%
1일 변동 폭
$6.3204
$7.32
1주일 범위
$5.414
$10.71
52주 변동 폭
$5.414
$3,360.00
22nd Century Group, Inc. Stock (XXII) Company Profile
명칭
22nd Century Group, Inc.
전화
716-270-1523
주소
8560 Main Street, Williamsville, NY
Compare XXII vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XXII
22nd Century Group, Inc.
|
6.545 | 109.06K | 15.74M | -12.86M | -8.71M | -231.13 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
22nd Century Group, Inc. Stock (XXII) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-21 | 개시 | Alliance Global Partners | Buy |
| 2022-06-15 | 개시 | Craig Hallum | Buy |
| 2022-03-08 | 개시 | ROTH Capital | Buy |
| 2021-07-23 | 개시 | Cowen | Outperform |
| 2017-10-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-08-11 | 재확인 | Chardan Capital Markets | Buy |
모두보기
22nd Century Group, Inc. 주식(XXII)의 최신 뉴스
3.02M warrant shares registered for resale by 22nd Century (XXII) - Stock Titan
Shareholder voting outcomes at 22nd Century Group (NASDAQ: XXII) - Stock Titan
22nd Century Group announces warrant inducement and 1-for-20 reverse stock split By Investing.com - Investing.com Australia
Warrant inducement and 1-for-20 reverse split at 22nd Century Group (XXII) - Stock Titan
22nd Century Group announces warrant inducement and 1-for-20 reverse stock split - Investing.com UK
22nd Century Raises $0.46M via Warrant Inducement, Redeems $2.01M Preferred; Hires Dawson James - TradingView
22nd Century (NASDAQ: XXII) sets warrant inducement and 1-for-20 split - Stock Titan
XXII Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
XXII News | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
XXII Stock Chart | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
22nd Century launches VLN cigarettes in California stores - Investing.com UK
22nd Century launches VLN cigarettes in California stores By Investing.com - Investing.com South Africa
22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes - The Manila Times
FDA-authorized low-nicotine cigarettes begin California test run - Stock Titan
XXII Stock Price, Quote & Chart | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers - Sahm
22nd Century Group (Nasdaq: XXII) Expands High-Margin - GlobeNewswire
22nd Century Group, IncCommon Stock (NQ: XXII - FinancialContent
22nd Century Group Expands Distribution of VLN® Cigarettes to 150 New Locations in Metro New York and Northern New Jersey - Quiver Quantitative
22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand - The Manila Times
22nd Century Group (Nasdaq: XXII) Ignites Major VLN Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand - Moomoo
FDA-authorized low-nicotine cigarettes target 800k NYC-area smokers - Stock Titan
22nd Century Group, Inc. (NASDAQ:XXII) Q1 2026 Earnings Call Transcript - Insider Monkey
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications - 2Firsts
22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review - The Manila Times
22nd Century Group Seeks FDA Renewal for VLN® as Modified Risk Tobacco Product - geneonline.com
XXII | 22nd Century Group Inc. FinancialsIncome Statement - Quiver Quantitative
22nd Century Group Seeks Renewal of Modified Risk Tobacco Product Status for VLN® King and VLN® Menthol King Cigarettes - Quiver Quantitative
Cigarettes with 95% less nicotine face new FDA review - Stock Titan
Fda to review two modified risk tobacco product renewal applications from 22nd Century Group - marketscreener.com
FDA To Review Two Modified Risk Tobacco Product Renewal Applications From 22nd Century Group - TradingView
22nd Century slightly lowers first-quarter loss; no net revenue from very-low-nicotine cigarettes - Winston-Salem Journal
FDA Files MRTP Renewal for Two 22nd Century Products - Tobacco Reporter
XXII Q1 2026 Earnings Call Transcript - The Globe and Mail
MSN Money - MSN
Number of shareholders of 22nd Century Group, Inc – NASDAQ:XXII - TradingView
22Nd Century Group IncQ1 Net Revenues Incr - Moomoo
Q1 2026 22nd Century Group Inc Earnings Call Transcript - GuruFocus
22nd Century Group, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
22nd Century: Q1 Earnings Snapshot - theheraldreview.com
22nd Century Group 1Q Loss $3.3M >XXII - Moomoo
Earnings call transcript: 22nd Century Group reports Q1 2026 financials By Investing.com - Investing.com South Africa
XXII: Sequential revenue up 16% in Q1 2026 as VLN retail expansion accelerates - TradingView
Earnings call transcript: 22nd Century Group reports Q1 2026 financials - Investing.com India
22nd Century Group Releases Q1 2026 Financial Results - AlphaStreet
22nd Century Group, Inc. (XXII) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):